Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in ...

Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

Several components of the hedgehog (Hh) pathway are crucial to basal cell carcinoma (BCC) tumorigenesis. Primary cilia have emerged as key organelles in Hh signal transduction in mammalian systems ...

Compr Ophthalmol Update. 2007;8(1):1-14. The micronodular (. 15%) variant shows smaller tumor nodules (< 0.15 mm by definition) (Figure 1C) and has an increased tendency for subclinical extension.

The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe Philadelphia ...

The basal state co-expresses both epithelial and mesenchymal programs and has a distinct epigenetic landscape with accessible chromatin across gene sets that mark cancer cell states with divergent ...

For Cancer Sun, Moon and rising, your focus will be on your career, reputation, and long-term ambitions. You will be engaging in strategic conversations, update your professional plans, or clarify ...